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Abstract
Background: Visceral leishmaniasis is a notifiable parasitic disease that had increased in incidence in our region on
the past few years. It is common in children. In adults, it occurs more on a background of immunodeficiency, and
frequently with incomplete clinical manifestations, making the diagnosis complicated.
Findings: The aim of our study is to reveal different features of visceral leishmaniasis in adults, through the analysis
of its epidemiological, clinical and biological parameters, in a group of 26 patients. No one was infected with HIV
or under immunosuppressive therapy Clinical presentation was generally conservative, but there was few
differences in adults compared to children, concerning both the clinical symptoms and the laboratory parameters.
Diagnosis was provided by direct examination of bone marrow smears in 24 cases (sensitivity 92%), and anti-
leishmanial serology in the others.
Conclusion: We should think to the diagnosis of VL even if the patient is not known immunocompromised, and
even if the clinical is incomplete, to avoid a delay of care which can lead to serious complications.
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Introduction
Visceral leishmaniasis (VL), also known as kala-azar, is a
systemic parasitic infection caused by two of the species
of the protozoan Leishmania : L. donovani and L. Infan-
tum. It is spread by the bite of the female sand fly Phle-
botomus [1]. It affects approximately 500.000 people
every year [2-4], and almost 1000 individuals in the
Mediterranean basin [5].
Its typical presentation associate fever, splenomegaly,
hepatomegaly, lymph node enlargement and pancytopenia.
Conventional laboratory techniques for the diagnosis
of VL are parasitological methods, based on the search
for parasites on bone marrow smears or other tissues,
and in vitro cultivation, and serological methods,
favoured by the presence of serum antibodies; the most
commonly used are immunofluorescent antibody test
(IFAT) and immunoenzymatic methods (ELISA). PCR
assays are also proposed as useful tools for the diagnosis
of VL, through the detection of Leishmania DNA in dif-
ferent biological samples such as peripheral blood and
bone marrow aspirate [1,4].
Through this retrospective analysis, we try to discuss
the specifics of VL in immunocompetent adults. Patients
included are beyond 15 years-old, collected in the inter-
nal medicine department at the University Hospital of
Fez, between June 2003 and August 2010. All of them
were not infected with HIV, and they all underwent a
bone marrow aspiration and a serological test of leish-
maniasis based on immunofluorescent antibody test
(IFAT) for the diagnosis.
Findings
We collected 26 cases of visceral leishmaniasis diag-
nosed in HIV-negative adults. Patients ranged in age
from 15 to 65 years, with mean ages of 28 years. There
were 15 men and 11 women. All patients were from
regions already known to be endemic foci of VL, 61% of
them were from rural areas, mainly from the vicinity of
Fez and Taounate wich are cities in the center of
Morocco.
Two patients were diabetic, one had chronic hepatitis
C, another suffered from chronic renal failure and in
two cases, VL was associated with pregnancy. We have
also noted the particular association of VL with perni-
cious anemia in a woman, and with a spondylarthropa-
thy in an adolescent.
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than half of our patients had consulted the first time for
abdominal symptoms. In other cases, hematological and
general symptoms were inaugural.
Clinical features of the 26 patients are summarized in
Table 1. 84% of our patients had fever, 81% had asthenia
and all of them had pallor. Splenomegaly was present in
84% of cases but hepatomegaly and lymph node enlarge-
ment were noted in only 35%. Respiratory signs were
rare.
Biologically (table 2), anemia was constant, non-regen-
erative, often normochromic and normocytic, with an
average hemoglobin of 7,51 g/dl; It was below 7 g/dl in
40% of cases. Leukopenia was also frequently observed
in 76% of cases and thrombocytopenia was less com-
mon. In 53% there was a severe neutropenia (< 1000
cells/mm
3). 11 patients had a platelet count less than
100.000/mm
3, 7 others had moderate thrombocytopenia
(between 100.000 and 130.000/mm
3), and 8 patients had
normal levels of platelets. The rate of serum protein was
elevated in 27% of cases, with an extreme of 120 g/l.
Most patients had an obvious inflammatory syndrome;
in 63% of them, the erythrocyte sedimentation rate
(ESR) exceeded 100 mm in the first hour and C-reactive
protein (CRP) was often above 50 mg/l and the average
value was 62,4 mg/L. only 10 patients had at admission
elevated liver enzymes levels, reaching more than 3
times the normal value.
Anti-Leishmania serology was performed in 13
patients by IFAT. It was positive in 12 of them. The
analysis of bone marrow smears, stained with May-
Grunwald-Giemsa, objectified the presence of Leishma-
nia amastigotes in 24 cases. The parasites were usually
scattered in the stroma in extracellular. Rarely they
regrouped in clusters, or were found inside the granulo-
cyte (Figure 1). In 2 cases, the myelogram was normal
and no Leishmania were demonstrated, probably
because of low parasitemia; the diagnosis was therefore
established on the basis of clinical and serological data.
An anti-HIV serology was performed in all patients
and was negative. It was the same for the serology for
hepatitis B and syphilis, made in 15 cases. One patient
was positive for Hepatitis C tests.
All patients were treated with injections of antimoni-
ate of Méglumine (Glucantime
®). They received a single
cure of 21 days at a dose of 80 mg/kg/day, administered
gradually. This treatment was generally well tolerated.
We have noted a single case of liver toxicity that
resolved after dose reduction of Glucantime
®.T h e r e
was no relapse in our series.
Table 1 Clinical characteristics of the 26 patients
Clinical data No. of patients Percentage
Fever 24 92
Sweats 22 84
Weight loss 11 42
Asthenia 21 81
Pallor 26 100
Haemorrhage 9 35
Splenomegaly 22 84
Hepatomegaly 9 35
Lymphadenopathy 9 35
Edema of lower limbs +/- ascites 2 7
Respiratory signs 3 11
Skin lesions 0 0
Table 2 Biological characteristics of the 26 patients
Parameter Average
value
Minimum
value
Maximum
value
Hemoglobin (g/dL) 7,51 5,1 10,5
White blood cells (cells/
mm
3)
3208 900 9400
Neutrophils (cells/
mm
3)
1524 380 7300
Lymphocytes (cells/
mm
3)
1207 110 3500
Platelets (10
3cells/mm
3) 131 34 394
ESR (mm/h) 99,63 19 150
CRP (mg/L) 62,4 5 219
Total protein (g/L) 81,7 62 120
ALAT (IU/L) 69,32 4 573
ASAT (IU/L) 80,72 5 674
Figure 1 Leishmania amastigotes in intracellular, revealed in a
Giemsa-stained bone marrow smears. Amastigotes of Leishmania
are spherical to ovoid and measure 1-5 μm long by 1-2 μm wide.
They possess a large nucleus, a prominent kinetoplast, and a short
axoneme, the last of which is rarely visible by light microscopy.
Lahlou et al. BMC Research Notes 2011, 4:389
http://www.biomedcentral.com/1756-0500/4/389
Page 2 of 5The outcome was favorable in 23 cases (88%), with a
progressive improvement in clinical parameters with
obtaining apyrexia, disappearing of splenomegaly and
improving general condition, then in biological assess-
ments with decreasing of the inflammatory syndrome
and normalization of the liver enzymes levels. No infec-
tious or hemorrhagic complications were recorded.
Although, the outcome in both pregnant women was
characterized by the occurrence of portal hypertension
in one, and fetal death in the other. We recorded an
unexplained death of a patient of 60 years-old with
renal failure, on the 4th day of treatment.
Epidemiological and etiopathogenic features
During the last years, a modification of the epidemiolo-
gical profile of VL was noted. This disease is, up to
now, quite rare among adults, became increasingly com-
mon, especially among immunocompromised indivi-
duals. In North-Mediterranean countries for example,
there was an inversion of VL case distribution according
to age [6,7], in relation to the spread of HIV infection
mainly, and also to the use of immunosuppressive thera-
pies, such as long-term corticosteroid treatments [8] and
immunosuppressants in systemic diseases, chemotherapy
for cancer, and transplant anti-rejection therapy in allo-
graft patients [9]. Any condition able to weaken immune
defenses of the host represents a fertile background for
the development of VL. This infection is therefore, cur-
rently considered as an opportunistic disease. Indeed,
several factors have been reported by various authors in
literature [10-13], namely diabetes, terminal chronic
renal failure, liver cirrhosis, tuberculosis, cancer, and
also pregnancy on account of hormonal and immune
changes which occur in pregnant women [14].
Nevertheless, several cases of VL were diagnosed in
apparently immunocompetent adults, especially in
North Africa, with significant proportions in most series.
They were around 57%, 45% and 40% according to Afrit
et al [11], Aoun et al [10] and Hakem et al [12]
respectively.
In our series, the HIV serology was negative each time
it was performed. None of our patients had received
immunosuppressive therapy, and only 8 cases of VL had
occurred on weakened immune terrain (diabetes, preg-
nancy, renal failure, hepatitis C, megaloblastic anemia
and spondylarthropathy). Probably and for the others,
it’s possible that virulent parasite strains have been
selected and may induce disorders even in adults [15].
Clinical presentation
Clinical manifestations of VL in adults are sometimes
discreet and are not always suggestive. Moreover, even
when a febrile hepatosplenic pancytopenic syndrome is
present, diagnosis is often delayed because those signs
are common to several other diseases [16] whose inci-
dence is higher in adults.
Our series included young adults (average age = 28
years) whose clinical manifestations were nonspecific,
represented mainly by fever, splenomegaly and anemic
syndrome. In comparison to an infant VL series (Figure
2) about 209 cases published by the pediatric depart-
ment of the same hospital [17], we deduce that clinical
presentation in our patients is generally conservative,
and the incidence of different symptoms is similar to
that of child, except for lymph node hypertrophy, clearly
more common in adults, this has been noted also in
other mediterranean series. Splenomegaly was present in
84% of cases, but contrary to the child, it was usually
moderate. Our result corresponds to that found in
another Moroccan series [18]. In other ones [10,11], this
sign was absent in almost half the cases. But in the large
series of 64 cases of Mediterranean VL in HIV-negative
adults reported by Pagliano et al [19], all patients had
hepatosplenomegaly (Table 3). Finally, anemic syndrome
seems to be the most constant symptom of VL in adults.
Nonspecific biological signs
Hemogram, erythrocyte sedimentation rate and electro-
phoresis of plasmatic proteins are the main tests in the
diagnosis process in VL. They show non-specific disor-
ders such the common anemia which is normochromic,
normocytic and non-regenerative. First moderate, then
it gets progressively worse during the evolution, but not
as fast as in children. Leukopenia, which was absent in
24% of our patients is, according to other authors,
Figure 2 Comparison of clinical and laboratory features of VL
in adults and in children (through an infant VL series about
209 cases published by the pediatric department of our
university hospital).
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delayed or may even miss [21], but late in disease pro-
gression, it is sometimes associated with alteration in
the synthesis of coagulation factors by the liver, causing
bleeding which can be serious or even fatal.
Inflammation is very marked; in fact, ESR that usually
reaches 50-80 mm the first hour in children [22], is
even higher among adults (99 mm in our series). CRP is
also greatly increased.
Total serum protein is highly variable; it may be nor-
mal or high, particularly in adults. However, electro-
phoresis of proteins is very disturbed almost steadily. It
shows a polyclonal hypergammaglobulinemia affecting
mainly IgG, with hypoalbuminemia [23].
Specific biological signs
As clinical presentation of VL and hemato-biochemical
disruption are unspecific, the detection of serum antibo-
dies by serology, or better yet, the visualization of the
parasite in any involved organ, are required for the diag-
nosis [24].
The anti-Leishmania antibodies are detected routinely
by direct immunofluorescence technique, ELISA or
indirect hemagglutination, and currently by immuno-
blotting on nitrocellulose membrane [25,26]. Serology
can be negative, despite the wealth of the bone marrow
in Leishmania, especially in immunodeficient patients
[6].
PCR also can be used; it may detect Leishmania DNA
in different biological samples such as peripheral blood
and bone marrow aspirate [4].
Concerning parasitological methods, the search for
parasites must be first in the bone marrow, and an
initial failure does not challenge the diagnosis. In immu-
nocompromised patients, we can even find Leishmania
on the peripheral blood after leukoconcentration.
In vitro cultivation has a good sensitivity but is carried
out only in specialized centers, and if is negative or if
the parasites are scanty, the results can be obtained only
after several weeks.
In our series, the identification of the parasite by
direct examination of the bone marrow allowed to the
diagnosis in 24 patients, which means a sensitivity of
92%, comparable to that reported in the literature
[27-29]. For the 2 patients whose bone marrow was
negative, the diagnosis of VL was selected on the results
of serology and clinical manifestations.
Conclusion
VL affects more and more adults in the Mediterranean
area. This means that special care must be given to
diagnosis, especially since clinical signs are often incom-
plete and little characteristic.
Thus, the disease should be suspected whenever there
is prolonged or unexplained fever, splenomegaly or
hypergammaglobulinemia in a patient from an endemic
area, even if he is not infected with HIV or receiving
immunosuppressive therapy. And when VL is diagnosed
in those adults, an underlying condition that could
weaken the immunity of the patient must be seeked, but
even if there is not, this does not rule out the diagnosis
of VL.
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Table 3 Comparison of different VL series in adults
Parameter (%) I. Benlbaghdadi [18]
(n = 6)
K. Aoun [10]
(n = 18)
M. Afrit [11]
(n = 7)
P. Pagliano [19]
(n = 64)
Our series
(n = 26)
Fever 100 83 100 94 92
Splenomegaly 83 55 57 100 84
Hepatomegaly 50 38 57 100 35
Pallor 100 94 100
Haemorrhage 17 35
Lymphadenopathy 33 14 35
Pancytopenia 83 22 57 56
Inflammatory syndrome 100 83 71 100
Hyperproteinemia 50 27
Hypergammaglobulinemia 100 94 57
Anti-Leishmania serology (+) 83 82 83 100 92
Amastigotes on bone marrow
smears
50 67 100 97 92
Favorable outcome 83 71 88
Deaths 1 case
(Hematemesis: PHT)
1 case
(Severe sepsis)
1 case
(Relapse)
1 case
(unexplained)
PHT = Portal hypertension
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